Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis-Reference-Cited by-同舟云学术

Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis

Published:2023-03 Issue:2 Volume:10 Page:
ISSN:2332-7812
Container-title:Neurology Neuroimmunology & Neuroinflammation
language:en
Short-container-title:Neurol Neuroimmunol Neuroinflamm

Author:

Ho Samantha¹,Oswald Eva¹,Wong Hoi Kiu¹,Vural Atay¹,Yilmaz Vuslat¹,Tüzün Erdem¹,Türkoğlu Recai¹,Straub Tobias¹,Meinl Ingrid¹,Thaler Franziska¹,Kümpfel Tania¹,Meinl Edgar¹,Mader Simone¹

Affiliation:

1. From the Institute of Clinical Neuroimmunology (S.H., E.O., H.K.W., A.V., I.M., F.T., T.K., E.M., S.M.), Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität München; Graduate School of Systemic Neurosciences (S.H.), Ludwig-Maximilians-Universität München, Germany; Department of Neurology (A.V.), Koc University School of Medicine; Department of Neuroscience (V.Y., E.T.), Aziz Sancar Institute of Experimental Medicine, Istanbul University; Department of Neurology (R.T.),...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical),Neurology

Link

https://www.neurology.org/doi/pdfdirect/10.1212/NXI.0000000000200083

Reference37 articles.

1. Role of B Cells in Multiple Sclerosis and Related Disorders

2. Targeting B Cells to Modify MS, NMOSD, and MOGAD

3. Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients

4. Features of Human CD3+CD20+ T Cells

5. Proinflammatory CD20 + T Cells are Differentially Affected by Multiple Sclerosis Therapeutics

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. B cell activating factor levels are linked to distinct B cell markers in multiple sclerosis and following B cell depletion and repopulation;Clinical Immunology;2024-01

2. Histologic manifestations of ocrelizumab‐associated intestinal and hepatic injury in patients with multiple sclerosis;Histopathology;2023-12-19

3. Ocrelizumab B cell depletion has no effect on HERV RNA expression in PBMC in MS patients;2023-11-10

4. Therapeutic targeting of gut‐originating regulatory B cells in neuroinflammatory diseases;European Journal of Immunology;2023-10-09

5. Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis;Multiple Sclerosis and Related Disorders;2023-07